RxDoctor Payments Data

Demetrios Katsikas, MD

Urology · Maryville, ILNPI 1457335762

Payments from drug & device makers

$6,063in general payments, 2019–2025

Across 227 payments — averaging $26.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myriad Genetic Laboratories, Inc.$776
  • Astellas Pharma US Inc$653
  • Johnson & Johnson$448
  • Pfizer$345
  • Neotract Inc.$341
  • Accord Healthcare, Inc.$330
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$5,82996%
  • Education$2354%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,063 in reported general payments places this provider in the 70th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$312,617
Medicare patients
786
Services billed
5,984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide155$2,204,752
ErleadaApalutamide27$388,979
OrgovyxRelugolix51$143,603
MyrbetriqMirabegron130$92,575
GemtesaVibegron102$92,160
Mirabegron ErMirabegron15$11,746
Tamsulosin Hcl723$9,217
Finasteride659$7,787
Oxybutynin Chloride ErOxybutynin Chloride177$3,906
Dutasteride54$1,831
Solifenacin Succinate14$1,390
Cephalexin29$580
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst30$455
Ciprofloxacin Hcl86$386
Alfuzosin Hcl ErAlfuzosin Hcl21$344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$653$2,297,327285 claims
Johnson & JohnsonErleada$448$388,97927 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$316$235,763153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 550 urology providers in Illinois.

Other urology in Maryville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →